Show Summary Details
Page of

Endocrine and metabolic complications of advanced cancer 

Endocrine and metabolic complications of advanced cancer
Chapter:
Endocrine and metabolic complications of advanced cancer
Author(s):

Max Watson

, Rachel Campbell

, Nandini Vallath

, Stephen Ward

, and Jo Wells

DOI:
10.1093/med/9780198745655.003.0015
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 August 2019

This chapter covers the common endocrine and metabolic complications associated with malignancies such as hypercalcaemia, SIADH, and changes in glucose metabolism. It also outlines a strategy for managing the patient with iatrogenic hyperglycaemia as well as the patient with diabetes mellitus in the last phase of life. Metabolic and endocrinological disorders have a profound impact on a patient’s physical and psychological well-being. These disorders are at times complex, but it is important to be aware of the associated endocrine and metabolic complications in advanced cancer as they can have a significant impact on morbidity and mortality. In addition, even when the underlying cancer may not be responsive to treatment, such symptoms may be reversible, which can have a significant benefit to the individual patient.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.